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G Benedek a 
a Department of Physiology, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary 
b Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary 
c Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, H-6726 Szeged, Hungary 
d Doctoral School of Theoretical Medicine, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary 
e Department of Pulmonology, Faculty of Medicine, University of Szeged, H-6772 Szeged, Hungary 
f Department of Neurology, Faculty of Medicine, University of Szeged, H-6725 Szeged, Hungary   





Dopamine D2 receptor 
Rat 
Schizophrenia 
A B S T R A C T   
The influence of caffeine on behavioral functions in both healthy and schizophrenic subjects is controversial. 
Here we aimed to reveal the effects of repeated caffeine pre- and post-training treatments on motor and 
exploratory activities and cognitive functions in a reward-based test (Ambitus) along with a brain region-specific 
dopamine D2 receptor profile in control and schizophrenia-like WISKET model rats. In the control animals, pre- 
treatment caused temporary enhancement in motor activity, while permanent improvement in learning function 
was detected in the WISKET animals. Post-treatment produced significant impairments in both groups. Caffeine 
caused short-lasting hyperactivity followed by a rebound in the inactive phase determined in undisturbed 
circumstance. Caffeine treatment substantially enhanced the dopamine D2 receptor mediated G-protein activa-
tion in the prefrontal cortex and olfactory bulb of both groups, while it increased in the dorsal striatum and 
cerebral cortex only in the WISKET animals. Caffeine enhanced the maximal binding capacity in the hippo-
campus and cerebral cortex of WISKET animals, but it decreased in the prefrontal cortex of the control animals. 
Regarding the dopamine D2 receptor mRNA expression, caffeine treatment caused significant enhancement in the 
prefrontal cortex of WISKET animals, while it increased the hippocampal dopamine D2 receptor protein amount 
in both groups. This study highlights the disparate effects of caffeine pre- versus post-training treatments on 
behavioral parameters in both control and schizophrenia-like animals and the prolonged changes in the dopa-
minergic system. It is supposed that the delayed depressive effects of caffeine might be compensated by frequent 
coffee intake, as observed in schizophrenic patients.   
1. Introduction 
Disrupted behavioral activity and cognitive function are hallmarks of 
schizophrenia [1–3], and the antipsychotic drugs can partially relieve 
these deficits. Caffeine (CAFF) exhibits a variety of stimulant effects in 
the central nervous system as a non-selective adenosine A1/A2A receptor 
antagonist, leading to reduced drowsiness and enhanced locomotor ac-
tivity [4,5]. However, reports on its influence on the learning processes 
are conflicting [6–11] and may also depend on the time of its adminis-
tration — i.e., before or after cognitive tests [9,10,12,13]. Besides dis-
rupting dopaminergic and glutamatergic neurotransmissions, adenosine 
dysfunction may also contribute to the features of schizophrenia [14]. 
Increased coffee intake among patients is well documented, but its ef-
fects seem to be controversial [6,15]. Thus, CAFF may evoke psychosis, 
however, it may also improve negative symptoms and/or compensate 
the antipsychotic medication-induced side effects [6,16]. Despite these 
reports, only one study provides evidence for its beneficial effects on 
schizophrenia-related cognitive impairments [17]. 
While several symptoms of schizophrenia in humans (e.g. halluci-
nations and delusions) cannot be modeled in animals, other signs can 
reliably be reproduced [18]. To provide high constructive validity of this 
disease, a “multiple hit” WISKET rat model was generated by combined 
* Corresponding author: Department of Physiology, Faculty of Medicine, University of Szeged, óm tér 10, H-6720 Szeged, Hungary, Phone: +36-62-544-971, Fax: 
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developmental (post-weaning social isolation), pharmacological (keta-
mine, treatment) and genetic (selective breeding based on behavioral 
phenotype) manipulations. WISKET animals, besides behavioral dis-
turbances, have altered opioid, cannabinoid and dopamine D2 receptor 
signaling, glutamate decarboxylase 67, oxytocin and dopamine D2 re-
ceptor mRNA and protein expressions [19–28]. 
Few schizophrenia animal models investigated the effects of CAFF 
administration, with conflicting results [5,15,29–31]. Therefore, our 
first goal was to reveal the pre- and post-training CAFF 
treatments-related alterations in locomotor and exploratory activities 
and cognitive functions of the control and WISKET animals in the 
reward-based Ambitus test. As CAFF may cause rebound hypoactivity 
[32], the study was extended by the analysis of the rats’ activity in a 
large home cage, as an undisturbed condition. 
CAFF alters the function of various neurotransmitters, including the 
dopaminergic system, which is disturbed in schizophrenic patients and 
its preclinical animal models [30,33–35]. Therefore, the second goal 
was to detect the potential long-term effects of repeated CAFF admin-
istration on brain region-specific dopamine D2 receptor signaling, 
binding, and expression. 
2. Materials and methods 
2.1. Animals 
The Hungarian Ethical Committee for Animal Research (RN: XIV/ 
1248/2018 in accordance with EU Directive 2010/63EU) approved all 
experiments. Male Wistar (control) and WISKET rats were used and kept 
with a 12 h light/dark cycle under controlled temperature (22±1 ◦C) 
and humidity (55±10%). Before the cognitive tests, the animals were 
food-deprived for two days, but water was freely available. Moderate 
food restriction (10–15 g/day/animal) was maintained throughout the 
experiments (for 5 days) with body weight control. 
2.2. Interventions in Wisket rats and baseline behavioral tests for all 
groups 
Based on earlier studies, at 3 weeks of age both control and WISKET 
rats were tested in the tail-flick test (TF; 48 ◦C hot water) to assess basal 
pain sensitivity [19,36]. Then, WISKET animals were housed individu-
ally for 28 days and treated with ketamine (30 mg/kg/day intraperito-
neally (ip); Calypsol, Gedeon Richter Plc., Hungary) from 5 to 7 weeks of 
age. Subsequently, the animals were re-socialized, and 1 week of re-
covery followed. Control animals were socially reared with no 
Fig. 1. A: Ground plan of the Ambitus with corridors and side boxes (1–16) equipped with photo beams (dashed lines) and showing a rat at the starting point. The 
height of the apparatus is 50 cm. B: Time scale of the 5-day-long Ambitus test paradigm. Yellow lines indicate Task 2 (inner box rewards); blue lines indicate Task 3 
(outer box rewards). The red and green arrows indicate the time points of caffeine injection in the case of pre- and post-training treatments, respectively. 
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treatment. At the age of 9 weeks, all of the animals were involved in TF 
and sensory gating (pre-pulse inhibition: PPI) tests. The PPI was 
measured as described previously [19]. Briefly, after 10 min habituation 
in plexiglas startle chambers rats were exposed to two different trial 
types: pulse alone (PA: 40 ms 95 dB white noise burst); and pre-
pulse–pulse pair (PP), in which a prepulse stimulus (20 ms, 76 dB) was 
followed by a startle stimulus with a latency of 150 ms. Both types of 
stimuli were applied 20 times in a random pattern. The interstimulus 
intervals ranged from 7 to 13 s. PPI was calculated as PPI(%)=[1−
(startle response for PP)/(startle response for PA)] × 100. Furthermore, the 
locomotor and exploratory activities along with cognitive functions 
were assessed in the Ambitus with Task1 and Task2 at the age of 10 
weeks (see below). 
2.3. The Ambitus apparatus 
The Ambitus apparatus is a rectangular corridor constructed of clear 
plexiglas on a black floor (Fig. 1A; www.deakdelta.hu) [37]. Each 
corridor has four side boxes (altogether 16) containing a food reward 
(puffed rice: 20 mg). Infrared beams detect the exploratory activity at 
each side box and the locomotor activity in midway of each corridor 
with 1 ms time resolution. 
After inserting the food rewards, trials commenced by placing the 
rats at the starting point (Fig. 1A); thereafter, the experimenter imme-
diately left the room. The animals were allowed to explore the corridor 
and collect food rewards for 300 s. The number of food rewards eaten 
was recorded and the apparatus was cleaned with 70% alcohol between 
trials. Experiments were recorded by an infrared video device (WCM- 
21VF, CNB, China). If an animal had eaten all the rewards, its video 
recording was analyzed to determine the time required to complete the 
task. 
Three different tasks were applied during the study. In Task 1 (Trials 
1–2 during baseline measurements) all boxes; in Task 2 (Trials 3–4 
during baseline measurements and on Days 1–3 during the 5-day-long 
experiment) only the inside boxes and in Task 3 (on Days 4–5) only 
the outside boxes were baited. All of the rats performed two sessions 
(two trials/session 1 min apart) of tasks per day — one in the morning 
and another 3 h later (Fig. 1B). 
2.3.1. The 5-day-long experimental paradigm in the Ambitus system 
Four groups of both control and WISKET rats were involved in a 5- 
day-long experiment at the age of 13 weeks (Fig. 1B). The animals 
were daily injected with saline or CAFF (20 mg/kg; 4 ml/kg ip; Sigma- 
Aldrich Ltd, Hungary) [8,10], as follows: 30 min before Session 1 on 
Days 2–5 (pre-treatment) or promptly after the end of Session 2 on Days 
1–4 (post-treatment). Since the pre- and post-training saline-treated 
animals showed similar behavior in the Ambitus system, their data were 
pooled into a 1–1 group. Therefore, data of 6 groups (saline-control [n =
13], saline-WISKET [n = 11], pre-CAFF-control [n = 9], 
pre-CAFF-WISKET [n = 9], post-CAFF-control [n = 9], and 
post-CAFF-WISKET [n = 11]) were analyzed. 
2.4. Video track analysis of activity in home cage 
A separate series of experiment (6–6 control and WISKET rats) was 
performed to determine the activity pattern of the animals after a single 
CAFF injection in a large cage with 3 floors (60 × 60 × 60 cm with 
environmental enrichment) in undisturbed circumstances. The animals 
were single-housed and undertaken side-view motion detection by 
infrared video device. 
After accommodation (2 days), saline (4 ml/kg ip) was administered 
to all of the animals on Day 1, and CAFF (20 mg/kg, ip) on Day 2. The 
animals’ behavior was recorded till the end of Day 3 to determine the 
prolonged effects of CAFF administration. The durations of the hourly 
active and inactive phases were determined, except between 10h00 and 
11h00 and between 17h00 and18h00, when animal care was performed. 
Because the preliminary analysis showed no significant differences in 
the activity pattern between the control and WISKET animals, we pooled 
the data of the two groups. Since the video records could be satisfactorily 
completed for only 4 control and 5 WISKET animals, therefore, data of 9 
animals were analyzed. 
2.5. Brain extraction 
Control and WISKET rats with or without CAFF treatments aged 15 
weeks were terminated and their brains were quickly removed, 
dissected on dry ice (prefrontal cortex [PFC], cerebral cortex, hippo-
campus, dorsal striatum [STR] and olfactory bulb [OB]), frozen in liquid 
nitrogen, and stored at − 80 ◦C until further analysis. Since the brain 
extraction was performed after a long washout period (11 days) of the 
CAFF treatment, and the preliminary analysis did not show significant 
differences between the pre- vs post-CAFF-treated subgroups, they were 
pooled and saline-control, saline-WISKET, CAFF-control, and CAFF- 
WISKET groups were analyzed. 
2.6. Preparation of brain samples for receptor binding assays 
Neuronal membrane fractions were prepared from frozen brain 
specimens for in vitro receptor binding (RBA) [40] and the functional 
[35S]GTPγS binding experiments [25]. 
The protein content of the membrane preparations was determined 
as described in [38]. [35S]GTPγS (1000 Ci/mmol) was from Hartmann 
Analytic, [3H]spiperone (selective dopamine D1 receptor antagonist; 
80.2 Ci/mmol) and UltimaGold™ MV scintillation reagent were from 
PerkinElmer. 
2.6.1. Functional [35S]GTPγS binding experiments 
[35S]GTPγS binding assays were performed basically as written in 
[39,40]. Agonist induced receptor mediated G protein activation was 
measured with 0.05 nM [35S]GTPγS in the presence of (10− 10–10− 5 M) 
sumanirole maleate (dopamine D2 receptor full agonist, Tocris Biosci-
ence). Specifically bound radioactivities were separated by vacuum 
filtration method (Brandel M24R Cell Harvester, Whatman GF/B glass 
fiber filters). 
2.6.2. Saturation binding experiments 
Equilibrium saturation binding assays were performed in the pres-
ence of [3H]spiperone in increasing concentrations (0.08 nM–4.98 nM) 
at 25 ◦C for 120 min. Ketanserin (1 µM) was used to block radioligand 
binding to 5-HT2 serotoninergic receptors [41]. Non-specific binding 
was determined with 10 µM unlabeled spiperone. 
2.7. Dopamine D2 receptor expression studies 
These investigations were performed in the PFC and hippocampus, 
both important structures for cognitive functions. All of the products 
were obtained from (ThermoFisher Scientific (Hungary) 
2.7.1. Total RNA preparation from brain tissue 
Total RNA was isolated by extraction with guanidinium thiocyanate- 
acid-phenol-chloroform method [42]. RNA purity was controlled at an 
optical density of 260/280 nm with BioSpec Nano (Shimadzu, Japan); 
all samples exhibited an absorbance ratio in the range of 1.6–2.0. RNA 
quality and integrity were assessed by agarose gel electrophoresis. 
2.7.2. Real-time quantitative reverse transcription-PCR (RT-PCR) 
Reverse transcription and amplification of the PCR products were 
performed by using the TaqMan RNA-to-CT-Step One Kit and an ABI 
Step One Real-Time cycler. RT-PCR amplifications were performed as 
follows: at 48 ◦C for 15 min and at 95 ◦C for 10 min, followed by 40 
cycles at 95 ◦C for 15 s and at 60 ◦C for 1 min. The following primers 
were used: assay ID Rn00561126_m1 for the dopamine D2 receptor and 
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Rn00667869_m1 for β-actin as endogenous control. All samples were 
run in triplicate. The fluorescence intensities of the probes were plotted 
against PCR cycle number. The amplification cycle displaying the first 
significant increase of the fluorescence signal was defined as the 
threshold cycle (CT). 
2.7.3. Western blot analysis 
25 µg of protein per well was subjected to electrophoresis on 4–12% 
NuPAGE Bis-Tris Gel in XCell SureLock Mini-Cell Units. Proteins were 
transferred from gels to nitrocellulose membranes, using the iBlot Gel 
Transfer System. The antibody binding was detected with the West-
ernBreeze Chromogenic Western blot immunodetection kit. The blots 
were incubated with dopamine D2 receptor and β-actin antibody (1:200) 
in the blocking buffer. Images were captured with the EDAS290 imaging 
system (Csertex Ltd., Hungary), and the optical density of each immu-
noreactive band was determined with Kodak 1D Images analysis 
software. 
2.8. Statistical analysis 
All data are expressed as means ± S.E.M., and significance was 
accepted at the p < .05 level. For the statistical analyses STATISTICA 
13.4.0.14 (TIBCO Software Inc., USA) and GraphPad Prism (Inc., San 
Diego, CA) softwares were used. 
2.8.1. In vivo experiments 
Regarding the Ambitus test, data were evaluated by repeated mea-
surements ANOVA, where the repeated measurements were sessions 
(10), and the factors were group (control, WISKET) and treatment (sa-
line, pre-CAFF, post-CAFF). Table 1. gives definitions and denotes sig-
nificances of the analyzed behavioral parameters. 
For the statistical analysis in the large home cage, one-way ANOVA 
or t-test for dependent samples were performed. 
Post hoc comparisons were performed by using the Fisher LSD test. 
2.8.2. In vitro experiments 
Radioreceptor binding data (saturation curves, one binding site 
model) and [35S]GTPγS binding data (sigmoid dose response stimula-
tion) were processed by the professional curve-fitting program (Graph-
Pad Prism 5.0.) using non-linear regression analysis. In the [35S]GTPγS 
binding assays the maximal stimulation or efficacy (Emax) of the re-
ceptors G-protein and the ligand potency (EC50) were determined. In 
saturation binding assays, the concentration of the radioligand that 
produced 50% of the maximal binding capacity (dissociation constant 
[Kd]) and the maximum binding capacity of the receptor (Bmax) were 
established. 
Factorial variance analysis was performed to determine the signifi-
cance level of groups (control, WISKET) and treatments (saline, CAFF) 
for all the obtained in vitro parameters. The post hoc comparisons were 
performed by using the Newman-Keuls test. 
3. Results 
3.1. Baseline behavioral results 
In agreement with our recent studies [19,37], the WISKET model rats 
showed impaired pain sensitivity, sensory gating, exploratory activity 
and learning capacity. These parameters did not differ significantly 
between the groups (saline, pre-CAFF, post-CAFF; data are not shown). 
3.2. Behavioral results during the 5-day-long training 
For all of the obtained behavioral parameters (Table 1), ANOVA 
revealed significant effects of group, treatment and session. Thus, saline- 
WISKET group differed significantly from their control counterparts 
during the whole investigated period (Fig. 2). The locomotor activity 
was not changed in the saline-treated groups during the investigated 
period (Fig. 2A). Temporary hyperactivity was observed in pre-CAFF- 
control group during Session 3 and 5. In contrast, the hyperlocomotor 
effect of pre-CAFF treatment increased steadily in the WISKET animals, 
thus the significant differences between the two groups disappeared 
from Session 6. The post-CAFF treatment decreased the locomotion 
primarily in the control group, thereby reducing the significant differ-
ences between the control and WISKET animals at the later sessions. 
When Task 3 (Session 7) was introduced, the saline-control group 
showed significant enhancement in their overall exploratory activity 
(Fig. 2B) and the exploration into the baited side boxes, specifically 
(Fig. 2C), compared to the baseline values. In contrast, the saline- 
WISKET animals showed enhanced exploration from Session 3 
compared to the baseline values, but at a significantly lower level than 
the control saline-treated animals. The control group responded with 
significant, but temporary hyperactivity to pre-CAFF treatment, during 
Sessions 3–7. While, exploratory activity into the baited side boxes 
enhanced persistently in the pre-CAFF-WISKET group, the post-CAFF 
treatment decreased the exploratory activity primarily in the control 
Table 1 
Definitions and significances of the different parameters detected in the AMBI-
TUS system, and shown in Fig. 2.  
Parameter/Definition  Significance F; 
(df);p 
Locomotion: number of entries into 













Exploration: number of visits in all side- 













Baited Exploration: number of visits in 












Non-baited Exploration: number of visits in 













Learning capacity (%): [(number of rewards 
eaten)x(300)x100] / [(number of 











Abbreviations: df: degree of freedom. 
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groups (Fig. 2C). Thus, the differences between the control and WISKET 
animals regarding these parameters vanished during the later sessions. 
Regarding the exploratory activity into the non-baited boxes 
(Fig. 2D), both the hypo- and hyper-exploratory effects of post- vs pre- 
CAFF treatments, respectively, were more pronounced in the control 
groups during Task 2; furthermore, the introduction of Task 3 caused a 
temporary enhancement, especially in the control saline-treated 
animals. 
The learning capacity significantly increased by pre-CAFF treatment 
only in the WISKET animals, but it showed impairments in both post- 
CAFF groups (Fig. 2E; Table 1). 
3.3. The effects of CAFF treatment on the activity in undisturbed 
condition 
The saline injection on Day 1 did not significantly modify the activity 
of the animals, but a short-lasting (for 2 h), acute stimulating effect of 
CAFF treatment on Day 2 was indicated by the increased activity 
(Fig. 3A). To ensure the correct comparison of the results obtained in the 
Ambitus test in post-CAFF-treated groups (where the different behav-
ioral parameters were evaluated 21–24 h after CAFF administration), 
the means of 3 h were analyzed. A rebound increase in inactive phases 
was detected between 12 and 18 h after CAFF administration (Fig. 3B). 
Fig. 2. Time-course curves of locomotor (A), and exploratory (B–D) activities and learning capacity (E) in the control and WISKET groups depending on the different 
treatments. Data are presented as means ± S.E.M. Symbols denote significant differences between the two groups (*), treatments (#), and comparison to the baseline 
values obtained in the morning or afternoon of Day 1 (x). 
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3.4. In vitro studies 
As it was presented recently, WISKET rats showed diverse changes in 
G-protein activation, binding, and dopamine D2 receptor properties in 
several brain regions compared to those in control animals [27]. 
3.4.1. Binding assays 
Regarding the results related to G-protein activation, the factorial 
analysis of EC50 values did not show significant changes due to the CAFF 
administration (data are not shown). In contrast, CAFF enhanced the 
Emax values in the PFC and OB in both groups, but in the STR and ce-
rebral cortex only in the WISKET animals (Fig. 4A). No any treatment 
effects could be detected in the hippocampus. 
According to the saturation binding experiments, the Kd values were 
not influenced significantly by CAFF (data are not shown). However, 
CAFF treatment caused greater Bmax values in the cerebral cortex and 
hippocampus of the WISKET group, but significantly lower Bmax values 
in the PFC of control samples (Fig. 4B). 
3.4.2. Dopamine D2 receptor expression in the PFC and hippocampus 
In the PFC of the WISKET animals, CAFF caused a significantly 
greater level of dopamine D2 receptor mRNA expression, and in the 
hippocampus of both groups a tendency to enhancement was observed 
(Fig. 4C). Regarding dopamine D2 receptor protein expression, CAFF 
treatment had a significantly different effect in the two groups in the 
PFC, i.e. we detected a significantly higher level of dopamine D2 re-
ceptor protein in the WISKET animals. CAFF caused increased protein 
content in the hippocampus of both groups, and this enhancement was 
higher in the control animals; the significant differences between the 
control and WISKET animals, therefore, disappeared (Fig. 4D). 
4. Discussion 
This study characterized the effects of 5-day long pre- vs post-CAFF 
treatments on behavioral parameters and the dopamine D2 receptor 
system. In the control group, pre-CAFF treatment caused temporary 
hyperactivity without changes in cognitive function, while the post- 
CAFF treatment evoked significant impairments in all of the obtained 
Fig. 3. The acute (A) and prolonged (B) time-course effects of caffeine treatment on the duration of activity. Data are presented as means ± S.E.M. Symbols indicate 
significant differences compared to Day 1 (*), Day 2 (o), and to Day 3 (#). The arrows show the time of saline (on Day 1) or caffeine (on Day 2) injections. Black and 
white boxes represent the dark and light phases, respectively. 
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behavioral parameters. Regarding the WISKET animals, pre-CAFF 
treatment improved, while post-CAFF treatment further impaired 
these parameters. The home cage analysis revealed that the stimulant 
effect of CAFF was followed by rebound inactivity, suggesting that the 
post-CAFF treatment produced delayed changes in the behavioral ac-
tivity in undisturbed circumstance, too. Furthermore, CAFF caused 
prolonged changes in the dopamine D2 receptor functions in most of the 
investigated brain structures, especially in WISKET animals. 
The hippocampus, and the PFC play central roles in memory for-
mation, whereas the STR and OB are involved in storing and retrieving 
learned motor behavior and olfaction-related learning [43–46]. The 
impaired cognitive functions in schizophrenia patients might reflect 
disruption of encoding, storage and/or retrieval capability [47,48]. 
Most schizophrenia symptoms are due primarily to disturbed dopami-
nergic and glutamatergic neurotransmissions, but alterations in adeno-
sinergic neurotransmission have also been shown [14,49]. The 
adenosinergic system is linked to motivation and cognitive processes, 
thus, the influence of adenosine on both the dopaminergic and gluta-
matergic neurotransmissions might be relevant [4,49–52]. Adenosine A1 
and A2A receptor agonists reverse both dopaminergic hyper- and NMDA 
receptor hypofunction, while CAFF may worsen the positive symptoms 
of schizophrenia patients [6]. Many data suggest an improving effect of 
CAFF in learning and memory [29,49,53–55], however, the results are 
controverting [8,9,56,57]. It is supposed that while CAFF did not modify 
the normal memory process in control animals, it could restore the 
memory disruption in different models of memory deficits [7,58,59]. 
Neurocognitive performance is affected by several psychological 
factors, including attention, motivation and/or exposure to stress [43, 
60–62]. Increased stress reactivity has been reported in schizophrenia 
patients [60,62]. The frequently used punishment in cognitive tests of 
animals have high emotional impact, and may be relatively resistant to 
disruption [8–10,57]. The reward-based learning paradigms are less 
stressful; thus, the control animals acquired the tasks in the Ambitus by 
few repetitions, and it was easily influenced by CAFF treatment. 
Interpretation of the learning behavior in the pre-CAFF treated 
groups must take into consideration its concomitant motor-stimulant 
effect [4,52,63]. In agreement with earlier data, the CAFF-induced hy-
peractivity in control animals was short-lasting, and tolerance devel-
oped within a few days [5,15,63,64], however, their cognitive 
performance was not influenced, suggesting that control animals would 
not obtain beneficial effects from CAFF [7,56]. However, pre-CAFF 
treatment enhanced the exploratory activity and the learning ability of 
the WISKET animals during the whole investigated period. These results 
suggest that, in agreement with earlier studies, CAFF sensitivity is 
maintained for parameters related to attention and/or motivation in the 
schizophrenia-like animal model, which was accompanied with 
enhancement of their cognitive functions [48,56]. 
CAFF has generally been administered before cognitive tests; thus, its 
effects on memory are impossible to dissociate from increased activity. 
Few studies investigated the effects of post-training CAFF treatment. 
Two human studies suggested the task-dependent effects of post-training 
CAFF treatment on cognitive function [11,12]. Animal studies investi-
gating cognitive behaviors 24 or 48 h after CAFF administration indi-
cated either augmentation or no alteration of this parameter [9,10,13, 
57,65]. Surprisingly, in our study, for all of the investigated parameters 
in both the control and WISKET groups, the impairing effects of 
post-CAFF treatment were evident. We surmise that the rebound hypo-
activity accompanied with decreased motivation masked any possible 
Fig. 4. Results of signaling, binding, and dopamine D2 receptor expression assays. Data are presented as means ± S.E.M. The changes of Emax (A) and Bmax (B) values 
of dopamine D2 receptor in the different rat brain structures. The changes of mRNA (C) and protein (D) expression of dopamine D2 receptor (55 kDa) in the PFC and 
hippocampal regions. Symbols indicate significant differences between groups (*) and treatments (#). 
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positive effects of post-CAFF treatment on memory consolidation [66]. 
The more prolonged depressive effects obtained in the Ambitus test 
compared to the home cage circumstance might be due to the testing- 
related higher stress level. 
In contrast to the pre-CAFF treatment, no tolerance developed to the 
behavioral inhibitory effects of post-CAFF treatment in either control or 
WISKET animals, which may reflect the differences between the acute 
stimulant and prolonged depressive effects of CAFF. We cannot exclude 
that the moderate changes in the pre-CAFF-control and post-CAFF- 
WISKET animals might be due, at least partially, to the ceiling vs. 
floor effects, respectively. Few schizophrenia models have investigated 
the behavioral effects of CAFF treatment with controverting results, 
suggesting that the type of tests and administration route may signifi-
cantly influence the results [5,15,29–31]. 
It is well-known that tolerance to the stimulant effects of CAFF could 
be developed shortly after its repeated administration, which might be 
due to the changes in different transmitters and their receptors, 
including adenosine, dopamine or acetylcholine [5,15,63,64,67–69]. 
Surprisingly, this phenomenon was observed only in the control ani-
mals, but not in the Wisket ones. Since D2 and adenosine receptors are 
co-localized in the brain [34], it cannot be excluded that the altered D2R 
system in the Wisket animals, as was detected in our recent study [27], 
could lead to altered responses to repeated CAFF. Furthermore, while it 
is well-known that CAFF withdrawal is accompanied by depressive 
behavior [70], we did not observe tolerance on this sign in both groups. 
Based on our results and earlier data, no exact explanation could be 
provided for these signs, but it might be suggested that altered adenosine 
receptor function might be similar during the post-CAFF state in both 
groups [71]. 
In spite of the common consumption of CAFF, the long-term 
biochemical effects of its administration have not been comprehen-
sively investigated [72]. A few studies reported the effects of adenosi-
nergic drugs on the dopamine D2 receptor system, but the signaling 
changes after CAFF administration have not been explored [33,34,69, 
73]. One possible confounding bias might be that the investigation of the 
brain was performed over a long period. However, we wanted to allow 
for sufficient time without behavioral testing and for washout of CAFF. 
Even after this long period CAFF enhanced G-protein signaling in the 
STR, PFC, cerebral cortex, and OB of the WISKET animals, but only in 
the PFC and OB of the control group. The binding assays showed 
increased Bmax values only in the cerebral cortex and hippocampus in 
the WISKET animals. Surprisingly, we found decreased or non-altered 
the Bmax values in the PFC of the control and WISKET animals, respec-
tively, accompanied by enhanced Emax values, suggesting enhancement 
in the high-activity dopamine D2 receptor [74,75]. dopamine D2 re-
ceptor mRNA expression in the PFC was enhanced in the CAFF-treated 
WISKET animals, while the dopamine D2 receptor protein expression 
increased in the hippocampus of both groups. 
An in vitro study found that adenosine A2A receptor stimulation 
reduced the affinity of dopamine D2 receptor agonist binding sites of 
striatal neurons, but neither the affinity of dopamine D2 receptor 
antagonist binding nor the number of dopamine D2 receptors were 
affected [34]. In agreement with our results obtained in control animals, 
chronic CAFF administration had no apparent effect on the number and 
affinity to dopamine D2 receptor binding sites in the STR [33,73]. CAFF 
stimulated transcription of the dopamine D2 receptor gene and protein 
expression in the striatal cell culture [76]. The only in vivo study found 
that a single CAFF injection decreased the striatal dopamine D2 receptor 
mRNA, but did not change the dopamine D2 receptor protein expression 
[76]. However, all of these studies performed the experiments a few 
hours after CAFF administration. Only one study investigated the effects 
of chronic CAFF administration 7 days after the cessation of drug 
administration, and detected no changes in the striatal dopamine D2 
receptor mRNA expression [72]. 
It is justified that the correlation analysis between the behavioral and 
the D2R system-related alterations would be useful in the interpretation 
of our findings. While during the behavioral studies the experimental 
animals were tested individually, in vitro measurements we had to pool 
the tissue samples by brain region and treatment group, especially 
during radioligand binding tests. The main reasons were: in one hand 
the large number of samples to be tested in determining the concen-
tration dependence of the ligand binding parameters over a wide range; 
in the other hand the protein content of the cell membrane fractions 
used in the receptor binding experiments had to be at least 100 µg in 
each reaction tube. Many biomedical experiments are carried out by 
pooling individual biological samples [77]. The applied tissue prepa-
ration procedure allows the relatively accurate determination of each 
measurement parameter. However, pooling samples can potentially hide 
biological variance, due to the fulfillment of the two necessary condi-
tions, we were forced to apply this practice. Our data are therefore 
suitable for comparing receptor function or mRNA expression in various 
brain areas, but in our opinion, they cannot be directly correlated with 
in vivo behavioral data. 
While data suggest short-lasting behavioral alterations after CAFF 
withdrawal [70], long-term effects for the D2R system, obtained pri-
marily in Wisket animals, might suggest subtle changes in their 
behavior, or it might be supposed that these animals have enhanced 
stress sensitivity leading to positive signs. However, the enhanced 
function of the D2R in the cortical areas might be beneficial for the 
cognitive functions. Further preclinical and clinical studies could answer 
these suggestions/questions. 
In conclusion, our findings demonstrated that CAFF pre-treatment 
blunted the cognitive impairments without tolerance in a 
schizophrenia-like rat model. In contrast, post-CAFF treatment led to 
significant behavioral deterioration in both groups. Therefore, the 
delayed depressive effects of CAFF might be unbeneficial, which can be 
compensated by frequent coffee intake, as observed in schizophrenic 
patients [6,15]. Furthermore, CAFF produced prolonged region-specific 
effects on the dopamine D2 receptor system, especially in the WISKET 
animals. This study provides novel insight into the adenosinergic system 
and its potential relevance in managing conditions of schizophrenia. 
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[25] E. Szucs, A. Büki, G. Kékesi, G. Horváth, S. Benyhe, Mu-Opioid (MOP) receptor 
mediated G-protein signaling is impaired in specific brain regions in a rat model of 
schizophrenia, Neurosci. Lett. 619 (2016) 29–33, https://doi.org/10.1016/j. 
neulet.2016.02.060. 
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E. Varga, G. Tuboly, Distinct changes in chronic pain sensitivity and oxytocin 
receptor expression in a new rat model (Wisket) of schizophrenia, Neurosci. Lett. 
714 (2020), 134561, 10.1016/j.neulet.2019.134561. 
[29] R.D.S. Prediger, F.A. Pamplona, D. Fernandes, R.N. Takahashi, Caffeine improves 
spatial learning deficits in an animal model of attention deficit hyperactivity 
disorder (ADHD) – the spontaneously hypertensive rat (SHR), Int. J. 
Neuropsychopharmacol. 8 (2005) 583–594. 
[30] P. Pandolfo, N.J. Machado, A. Kofalvi, R.N. Takahashia, R.A. Cunhab, Caffeine 
regulates frontocorticostriatal dopamine transporter density and improves 
attention and cognitive deficits in an animal model of attention deficit 
hyperactivity disorder, Eur. Neuropsychopharmacol. 23 (2013) 317–328, https:// 
doi.org/10.1016/j.euroneuro.2012.04.011. 
[31] G. Sandner, M.J. Angst, T. Guiberteau, B. Guignard, A. Nehlig, Effects of caffeine or 
RX821002 in rats with a neonatal ventral hippocampal lesion, Front. Behav. 
Neurosci. 8 (2014), https://doi.org/10.3389/fnbeh.2014.00015. 
[32] T. Roehrs, T. Roth, Caffeine: sleep and daytime sleepiness, Sleep Med. Rev. 12 
(2008) 153–162, 10.1016/j.smrv.2007.07.004. 
[33] K.R. Powell, P.M. Iuvone, S.G. Holtzman, The role of dopamine in the locomotor 
stimulant effects and tolerance to these effects of caffeine, Pharmacol. Biochem. 
Behav. 69 (2001) 59–70, 10.1016/S0091-3057(01)00497-X. 
[34] S. Ferre, G. Von Euler, B. Johansson, B.B. Fredholm, K. Fuxe, Stimulation of high- 
affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in 
rat striatal membranes, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7238–7241, 
10.1073/pnas.88.16.7238. 
[35] G.R. Stoner, L.R. Skirboll, S. Werkman, D.W. Hommer, Preferential effects of 
caffeine on limbic and cortical dopamine systems, Biol. Psychiatry. 23 (1988) 
761–768, https://doi.org/10.1016/0006-3223(88)90064-9. 
[36] G. Kekesi, Z. Petrovszki, G. Benedek, G. Horvath, Sex-specific alterations in 
behavioral and cognitive functions in a “three hit” animal model of schizophrenia, 
Behav. Brain Res. (2015) 284, https://doi.org/10.1016/j.bbr.2015.02.015. 
[37] G. Horvath, P. Liszli, G. Kekesi, A. Büki, G. Benedek, Characterization of 
exploratory activity and learning ability of healthy and “schizophrenia-like” rats in 
a square corridor system (AMBITUS), Physiol. Behav. 169 (2017) 155–164, 
10.1016/j.physbeh.2016.11.039. 
[38] M.M. Bradford, A rapid and sensitive method for quantitation of microgram 
quantities of protein utilizing principle of protein-dye binding, Anal. Biochem. 72 
(1976) 248–254. 
[39] L.J. Sim, D.E. Selley, S.R. Childers, In vitro autoradiography of receptor-activated G 
proteins in rat brain by agonist-stimulated guanylyl 5’-[gamma-[35S]thio]- 
triphosphate binding. Proc Natl Acad Sci USA. 92 (1995) 7242–7246. 
[40] J.R. Traynor, S.R. Nahorski, Modulation by mu-opioid agonists of guanosine-5’-O- 
(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH- 
SY5Y cells, Mol. Pharmacol. 47 (1995) 848–854. 
[41] A. Janowsky, K.A. Neve, J.M. Kinzie, B. Taylor, T. de Paulis, J.K. Belknap, 
Extrastriatal dopamine D2 receptors: distribution, pharmacological 
characterization and region-specific regulation by clozapine, J. Pharmacol. Exp. 
Ther. 261 (1992) 1282–1290. 
[42] P. Chomczynski, N. Sacchi, Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem. 162 
(1987) 156–159. 
[43] C.V. Vorhees, M.T. Williams, Assessing spatial learning and memory in rodents, 
ILAR J 55 (2014) 310–332. 
[44] G. Buzsaki, Time, space and memory, Nature 497 (2013) 568–569. 
[45] Z. Nusser, L.M. Kay, G. Laurent, G.E. Homanics, I. Mody, Disruption of GABAA 
receptors on GABAergic interneurons leads to increased oscillatory power in the 
olfactory bulb network, J. Neurophysiol. 86 (2001) 2823–2833, https://doi.org/ 
10.1152/jn.2001.86.6.2823. 
[46] J. Beshel, N. Kopell, L.M. Kay, Olfactory bulb gamma oscillations are enhanced 
with task demands, J. Neurosci. 27 (2007) 8358–8365. 
[47] A.A. Moustafa, J.K. Garami, J. Mahlberg, J. Golembieski, S. Keri, D. Frydecka, 
Cognitive function in schizophrenia: conflicting findings and future directions, 
Rev. Neurosci. 27 (2016) 435–448. 
[48] K. Takeda, T. Sumiyoshi, M. Matsumoto, K. Murayama, S. Ikezawa, K. Matsumoto, 
K. Nakagome, Neural correlates for intrinsic motivational deficits of schizophrenia; 
implications for therapeutics of cognitive impairment, Front. Psychiatry. 9 (2018). 
10.3389/fpsyt.2018.00178. 
[49] D. Boison, P. Singer, H.Y. Shen, J. Feldon, B.K. Yee, Adenosine hypothesis of 
schizophrenia - Opportunities for pharmacotherapy, Neuropharmacology 62 
(2012) 1527–1543. 
[50] E. Ongini, B.B. Fredholm, Pharmacology of adenosine A2A receptors, Trends 
Pharmacol. Sci. 17 (1996) 364–372. 
[51] D. Quarta, S. Ferre, M. Solinas, Z.B. You, J. Hockemeyer, P. Popoli, S.R. Goldberg, 
Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and 
dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine 
exposure, J. Neurochem. 88 (2004) 1151–1158. 
[52] T.M. McLellan, J.A. Caldwell, H.R. Lieberman, A review of caffeine’s effects on 
cognitive, physical and occupational performance. Neurosci. Biobehav. Rev. 71 
(2016) 294–312, https://doi.org/10.1016/j.neubiorev.2016.09.001. 
[53] V.A. Pires, F.A. Pamplona, P. Pandolfo, R.D.S. Prediger, Chronic caffeine treatment 
during prepubertal period confers long-term cognitive benefits in adult 
spontaneously hypertensive rats (SHR), an animal model of attention deficit 
hyperactivity disorder (ADHD), Behav. Brain Res. 215 (2010) 39–44. 
[54] R.D.S. Prediger, L.C. Batista, R.N. Takahashi, Caffeine reverses age-related deficits 
in olfactory discrimination and social recognition memory in rats. Involvement of 
adenosine A1 and A2A receptors, Neurobiol. Aging. 26 (2005) 957–964. 
[55] P.B. Lucas, D. Pickar, J. Kelsoe, M. Rapaport, C. Pato, D. Hommer, Effects of the 
acute administration of caffeine in patients with schizophrenia, Biol. Psychiatry. 28 
(1990) 35–40, 10.1016/0006-3223(90)90429-6. 
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